Due to the unpredictable course and heterogenous treatment response in multiple sclerosis
(MS), there is a clear need for biomarkers that reflect disease activity in the clinical follow-up …

Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple
sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 …

Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody approved in more than 50
countries. Within the European Union, alemtuzumab is indicated for the treatment of adult …

Background Treatment of neuromyelitis optica spectrum disorder (NMOSD) has so far been
based on retrospective case series. The results of six randomized clinical trials including five …

Objective: To compare the Expanded Disability Status Scale (EDSS) and self-rated quality of
life scores (SF-36 Health Survey) as measures of disease impact in a representative sample …

The discriminating variable (DIVA) test and the selectivity ratio (SR) plot are developed as
quantitative tools for revealing the variables in spectral or chromatographic profiles …

Background and Purpose—We sought to compare health-related quality of life (HRQoL) in
young adults with ischemic stroke on long-term follow-up with controls and to evaluate …

This work presents a new method for variable selection in complex spectral profiles. The
method is validated by comparing samples from cerebrospinal fluid (CSF) with the same …

Objective Survival and causes of death (COD) in multiple sclerosis (MS) provide ultimate
endpoints. We aimed to investigate survival and COD in a 60-year population-based MS …

Objectives To identify MRI biomarkers associated with long-term disability progression in
patients with multiple sclerosis (MS), and to define the rate of evolution of global, tissue …